Recombinant Human KIR3DL3/CD158z Fc Chimera Protein, CF

When Recombinant Human B7-H7/HHLA2 His-tag (10475-B7) is immobilized at 2 μg/mL (100 µL/well), the concentration of Recombinant Human KIR3DL3/CD158z Fc Chimera (Catalog # 10104-KR) that produces 50% of the optimal binding response is found to be approximately 45.0‑270 ng/mL

2 μg/lane of Recombinant Human KIR3DL3/CD158z Fc Chimera (Catalog # 10104-KR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 62-71 kDa and 120-140 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human KIR3DL3/CD158z Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human B7-H7/HHLA2 His-tag Protein, CF (Catalog # 10475-B7) is immobilized at 2 μg/mL (100 µL/well), the concentration of Recombinant Human KIR3DL3/CD158z Fc Chimera (Catalog # 10104-KR) that produces 50% of the optimal binding response is found to be approximately 45.0-270 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human KIR3DL3/CD158z protein
  

  Human KIR3DL3/CD158z (Gln26-Leu322) Accession # NP_703144.2	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: NP_703144.2
• N-terminal Sequence: Gln26; blocked
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 59 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 62-71 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human KIR3DL3/CD158z Fc Chimera Protein, CF

• CD158z
• CD158Z;Killer cell immunoglobulin-like receptor 3DL3;KIR2DL5B;KIR3DL7;KIR44;KIRC1
• KIR3DL3
• KIR3DL7
• KIR44
• KIRC1

Background

KIR3DL3 (also known as CD158z, KIR3DL7, KIR44, or KIRC1) is a type I transmembrane glycoprotein that belongs to the killer cell Ig-like receptor (KIR) family. KIRs are expressed on CD56dim NK cells and T cell subsets where they regulate effector functions in the innate immune system (1-4). KIRs are named for the number of Ig-like domains (2D or 3D) in the extracellular domain (ECD), and whether they have long or short (L, S) cytoplasmic tails. Human KIR3DL3 cDNA encodes a 410 amino acid (aa) polypeptide precursor with a 25 aa signal peptide, a 297 aa extracellular domain (ECD) with 3 Ig-like domains (3D), a 21 aa transmembrane domain, and a 67 aa cytoplasmic domain (long). Within ECD human KIR3DL3 shares 47% and 44% aa sequence identity with mouse and rat KIR3DL3, respectively. KIR3DL3 is ubiquitously present in every individual across diverse populations, however little is known about specific functions (5). The limited knowledge of KIR3DL3 expression does suggest involvement in reproduction, likely during placentation (4). KIR3DL3 likely encodes an NK cell inhibitory receptor (6). Recent studies have shown that KIR3DL3 binding and function require both receptor aggregation and inhibitory signal attenuation (7).

1. Colonna, M. and J. Samaridis (1995) Science 268:405.
2. Lanier, L.L. (2005) Annu. Rev. Immunol. 23:225.
3. Uhrberg, M. et al. (1997) Immunity 7:753.
4. Trundley, A.E. et al. (2006) Immunogenetics 57:904.
5. Hollenbach, J.A. et al. (2012) Immunogenetics 64:719.
6. Torkar, M. et al. (1998) Eur. J. Immunol. 28:3959.
7. Leaton, L.A. et al. (2019) Front. Immunol. 10:24.

Bioinformatics

• Uniprot:
  • NP_703144.2()